Axelle Cadoret

Dr. Axelle Cadoret

CRSA UMR_S938
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2002 in Oncogene
Verified
Journal Article
Closed access
ACAxelle Cadoret
Axelle Cadoret
COChristine Ovejero
Christine Ovejero
BTBenoit Terris
Benoit Terris
ESEvelyne Souil
Evelyne Souil
LLLaurence Lévy
Laurence Lévy
CPChristine Perret
Christine Perret

11 January 2001 in Oncogene
Verified
Journal Article
Closed access
CDChristèle Desbois-Mouthon
Christèle Desbois-Mouthon
ACAxelle Cadoret
Axelle Cadoret
MEMarie-José Blivet-Van Eggelpoël
Marie-José Blivet-Van Eggelpoël
FBFrance Bertrand
France Bertrand
GCGisèle Cherqui
Gisèle Cherqui
JCJacqueline Capeau
Jacqueline Capeau

1 April 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
AMAmine Majdi
Amine Majdi
LALynda Aoudjehane
Lynda Aoudjehane
VRVlad Ratziu
Vlad Ratziu
TITawhidul Islam
Tawhidul Islam
MAMarta B. Afonso
Marta B. Afonso
JGJérémie Gautheron
Jérémie Gautheron

1 July 2013 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SLSara Lemoinne
Sara Lemoinne
ACAxelle Cadoret
Axelle Cadoret
HMHaquima El Mourabit
Haquima El Mourabit
DTDominique Thabut
Dominique Thabut
CHChantal Housset
Chantal Housset

12 July 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
SLSara Lemoinne
Sara Lemoinne
ACAxelle Cadoret
Axelle Cadoret
PRPierre‐Emmanuel Rautou
Pierre‐Emmanuel Rautou
HMHaquima El Mourabit
Haquima El Mourabit
VRVlad Ratziu
Vlad Ratziu
DTDominique Thabut
Dominique Thabut
Liver fibrosis expanding from portal tracts and vascular remodeling are determinant factors in the progression of liver diseases to cirrhosis. In the present study, we examined the potential contribution of portal myofibroblasts (PMFs) to the vascular changes leading to cirrhosis. The analyses of liver cells based on the transcriptome of rat PMFs, compared to hepatic stellate cell HSC‐derived myofibroblasts in culture, identified collagen, type XV, alpha 1 (COL15A1) as a marker of PMFs. Normal liver contained rare COL15A1‐immunoreactive cells adjacent to the bile ducts and canals of Hering in the portal area. A marked increase in COL15A1 expression occurred together with that of the endothelial marker, von Willebrand factor, in human and rat liver tissue, at advanced stages of fibrosis caused by either biliary or hepatocellular injury. In cirrhotic liver, COL15A1‐expressing PMFs adopted a perivascular distribution outlining vascular capillaries proximal to reactive ductules, within large fibrotic septa. The effect of PMFs on endothelial cells (ECs) was evaluated by in vitro and in vivo angiogenesis assays. PMF‐conditioned medium increased the migration and tubulogenesis of liver ECs as well as human umbilical vein ECs and triggered angiogenesis within Matrigel plugs in mice. In coculture, PMFs developed intercellular junctions with ECs and enhanced the formation of vascular structures. PMFs released vascular endothelial growth factor (VEGF)A‐containing microparticles, which activated VEGF receptor 2 in ECs and largely mediated their proangiogenic effect. Cholangiocytes potentiated the angiogenic properties of PMFs by increasing VEGFA expression and microparticle shedding in these cells. Conclusion: PMFs are key cells in hepatic vascular remodeling. They signal to ECs through VEGFA‐laden microparticles and act as mural cells for newly formed vessels, driving scar progression from portal tracts into the parenchyma. (Hepatology 2015;61:1041–1055)

7 January 1999 in Oncogene
Verified
Journal Article
Closed access
OLOlivier Lorentz
Olivier Lorentz
ACAxelle Cadoret
Axelle Cadoret
IDIsabelle Duluc
Isabelle Duluc
JCJacqueline Capeau
Jacqueline Capeau
CGChristian Gespach
Christian Gespach
JFJean-Noel FREUND
Jean-Noel FREUND